The efficacy and potential mechanism of Danggui Buxue Decoction in treating diabetic nephropathy: A meta-analysis and network pharmacology

Background: To evaluate the efficacy and potential pharmacological mechanisms of Danggui Buxue Decoction (DGBXD) in the treatment of diabetic nephropathy. Methods: Meta-analysis was used to conduct a comprehensive search of the literature for randomized controlled trials of DGBXD for diabetic nephropathy, followed by identification of quantitative literature based on inclusion and exclusion criteria, and statistical analysis of the included data using Review Manager. The network pharmacology technique was used to screen the chemical components of DGBXD and their targets, disease targets, shared targets, and other associated information, and then apply bioinformatics technologies to annotate the key pathways. Using AutoDock and PyMol software, the 6 core targets were docked with the 7 main active components of DGBXD. Results: DGBXD complementary treatment significantly reduced 24 hours UTP, SCr and BUN levels and lowered blood glucose and lipid levels, improving clinical outcomes and modulating inflammatory factor levels. 22 active ingredients and 209 active targets were obtained for DGBXD, 245 core targets were obtained for diabetic nephropathy. The molecular docking results showed that all 7 components of DGBXD docked with 6 core targets had binding energies below −5. Conclusions: The findings suggest that DGBXD affects diabetic nephropathy through a multi-target, multi-component and multi-pathway mechanism.

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  Kai Yin,et al.  Formononetin Attenuates Renal Tubular Injury and Mitochondrial Damage in Diabetic Nephropathy Partly via Regulating Sirt1/PGC-1α Pathway , 2022, Frontiers in Pharmacology.

[3]  T. Chowdhury,et al.  Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease , 2022, Diabetic medicine : a journal of the British Diabetic Association.

[4]  F. Gao,et al.  Clinical Efficacy Evaluation and Potential Mechanism of Zhishe Tongluo Capsule in the Treatment of Cerebral Infarction by Meta-Analysis Associated with Network Pharmacology , 2022, Evidence-based complementary and alternative medicine : eCAM.

[5]  G. S. Kiran,et al.  Anti-diabetic Potential of a Stigmasterol From the Seaweed Gelidium spinosum and Its Application in the Formulation of Nanoemulsion Conjugate for the Development of Functional Biscuits , 2021, Frontiers in Nutrition.

[6]  Jiajun Liang,et al.  Exploring the Potential Mechanism of Tang-Shen-Ning Decoction against Diabetic Nephropathy Based on the Combination of Network Pharmacology and Experimental Validation , 2021, Evidence-based complementary and alternative medicine : eCAM.

[7]  N. Samsu Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment , 2021, BioMed research international.

[8]  Xiao-yun Zhu,et al.  Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation , 2021, International journal of molecular medicine.

[9]  Shanshan Ding,et al.  Based on Network Pharmacology and Molecular Docking to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Diabetic Nephropathy , 2021, Evidence-based complementary and alternative medicine : eCAM.

[10]  L. Merker Nierenschaden bei Diabetes frühzeitig erkennen! , 2021, MMW - Fortschritte der Medizin.

[11]  A. Alshehri Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2/Ho-1/antioxidants axis , 2021, Archives of physiology and biochemistry.

[12]  G. Bakris,et al.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.

[13]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[14]  Q. Jia,et al.  Tripterygium and its extracts for diabetic nephropathy: Efficacy and pharmacological mechanisms. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  Cuicui Chen,et al.  Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-β1/Smad/miR-192 signaling pathway , 2019, Experimental and therapeutic medicine.

[16]  Xiao-Qiang Li,et al.  A branched arabinoglucan from Angelica sinensis ameliorates diabetic renal damage in rats , 2019, Phytotherapy research : PTR.

[17]  J. Lewis,et al.  Update on Diabetic Nephropathy: Core Curriculum 2018. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  I. Narita,et al.  Clinico-pathological features of kidney disease in diabetic cases , 2018, Clinical and Experimental Nephrology.

[19]  Kaiping Wang,et al.  Retraction notice to "Polysaccharide from Angelica sinensis ameliorates high-fat diet and STZ-induced hepatic oxidative stress and inflammation in diabetic mice by activating Sirt1-AMPK pathway" [JNB 43 (2017) 88-97]. , 2017, The Journal of nutritional biochemistry.

[20]  Rui Zhang,et al.  Danggui buxue tang suppresses high glucose-induced proliferation and extracellular matrix accumulation of mesangial cells via inhibiting lncRNA PVT1. , 2017, American journal of translational research.

[21]  Z. Wang,et al.  Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway , 2017, Molecular and Cellular Biochemistry.

[22]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[23]  Tai-sheng Ye,et al.  Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus. , 2016, Experimental and therapeutic medicine.

[24]  R. Niles,et al.  Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease. , 2014, Nutrition reviews.

[25]  A. Ingsathit,et al.  Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis , 2011, Diabetologia.

[26]  S. Bhattamisra,et al.  Diabetic nephropathy: An update on pathogenesis and drug development. , 2019, Diabetes & metabolic syndrome.

[27]  P. Bogdański,et al.  Diabetic nephropathy in the elderly – clinical practice , 2018, Roczniki Panstwowego Zakladu Higieny.